TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15754276

Group type: EXPERIMENTAL
Intervention: Intravenous ascorbate (250 mg/wk, subsequently increased to 500 mg/wk)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intravenous ascorbate (500 mg/wk)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intravenous ascorbate (250 mg/wk and 500 mg/wk)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intravenous ascorbate (during supplementation)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Reference untreated cases
Number of subjects: 30
Study: 12401606

Group type: EXPERIMENTAL
Intervention: Hyperbaric lidocaine 25 mg with fentanyl 20 microg (n = 37)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Hyperbaric ropivacaine 4 mg with fentanyl 20 microg (n = 35)
Number of subjects: 72
Study: 10190377

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 100 mg twice daily for 3 days
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: Ofloxacin 200 mg twice daily for 3 days
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole 160/800 mg twice daily for 3 days
Number of subjects: 688
Study: 7549296

Group type: EXPERIMENTAL
Intervention: Hypo-osmolar ORS containing L-alanine and glucose (osmolality 255 mosmol/l)
Number of subjects: 55

Group type: COMPARATOR
Intervention: WHO-ORS (osmolality 311 mosmol/l)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: i.v. polyelectrolyte solutions (osmolality 293 mosmol/l)
Number of subjects: 55
Study: 2184789

Group type: EXPERIMENTAL
Intervention: Diet counseling
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Diet counseling with exercise
Number of subjects: 66
Study: 33969

Group type: EXPERIMENTAL
Intervention: Ethopropazine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Benztropine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Procyclidine
Number of subjects: 60
Study: 30927373

Group type: EXPERIMENTAL
Intervention: Diabetes (per doubling of the probability)
Number of subjects: 3541
Study: 30403154

Group type: EXPERIMENTAL
Intervention: Cyanoacrylate closure
Number of subjects: 222

Group type: COMPARATOR
Intervention: Radiofrequency ablation
Number of subjects: 222
Study: 29845481

Group type: EXPERIMENTAL
Intervention: Intravenous tramadol 100 mg
Number of subjects: 46

Group type: COMPARATOR
Intervention: Intravenous ketorolac 30 mg
Number of subjects: 46
Study: 27097315

Group type: EXPERIMENTAL
Intervention: Personalized emails encouraging application (n = 1,976)
Number of subjects: 3945

Group type: COMPARATOR
Intervention: Control group (n = 1,969)
Number of subjects: 3945
Study: 24152080

Group type: EXPERIMENTAL
Intervention: EmbaGYN with Kegel exercises
Number of subjects: 83
Study: 22779216

Group type: EXPERIMENTAL
Intervention: New dentifrice containing 8.0% arginine, calcium carbonate, and 1000 ppm fluoride (sodium monofluorophosphate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercially available dentifrice containing 2% potassium ion (potassium nitrate)
Number of subjects: 0
Study: 20540445

Group type: EXPERIMENTAL
Intervention: Lower Body Positive Pressure (LBPP) at 100% BW
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lower Body Positive Pressure (LBPP) at 66% BW
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lower Body Positive Pressure (LBPP) at 33% BW
Number of subjects: 10
Study: 18236180

Group type: EXPERIMENTAL
Intervention: Highly cross‐linked polyethylene (Durasul)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Highly cross‐linked polyethylene (Longevity)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional polyethylene
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Highly crosslinked polyethylene
Number of subjects: 60
Study: 15777304

Group type: EXPERIMENTAL
Intervention: Intravenous PCA morphine plus ketorolac (K group)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Intravenous PCA morphine (M group)
Number of subjects: 79
Study: 12007762

Group type: EXPERIMENTAL
Intervention: Mirtazapine 15 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mirtazapine 30 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mirtazapine (15 mg or 30 mg)
Number of subjects: 20
Study: 10715786

Group type: EXPERIMENTAL
Intervention: EVL treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 7767523

Group type: EXPERIMENTAL
Intervention: NPPV (noninvasive positive pressure ventilation) administered by nasal mask connected to a BiPAP device
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard therapy alone (control)
Number of subjects: 31
Study: 2137977

Group type: EXPERIMENTAL
Intervention: Nafarelin
Number of subjects: 23

Group type: COMPARATOR
Intervention: Danazol
Number of subjects: 23
Study: 10249190

Group type: EXPERIMENTAL
Intervention: Comprehensive intervention (emotional support and information about hospitalization)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emotional support only
Number of subjects: 0
Study: 31755959

Group type: EXPERIMENTAL
Intervention: Group 1 (anti-MDA5 positive)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Group 2 (other JIIM)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Unconventional treatment (more than two lines)
Number of subjects: 64
Study: 29189218

Group type: EXPERIMENTAL
Intervention: Bryan Cervical Disc Prosthesis
Number of subjects: 70

Group type: COMPARATOR
Intervention: ACDF
Number of subjects: 70
Study: 26563657

Group type: EXPERIMENTAL
Intervention: Teaching ophthalmoscope
Number of subjects: 55

Group type: COMPARATOR
Intervention: Conventional direct ophthalmoscope
Number of subjects: 55
Study: 24880955

Group type: EXPERIMENTAL
Intervention: Beger procedure
Number of subjects: 74

Group type: COMPARATOR
Intervention: Frey procedure
Number of subjects: 74
Study: 21782401

Group type: EXPERIMENTAL
Intervention: Vitamin E (800 IU)
Number of subjects: 455

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 455
Study: 19710199

Group type: EXPERIMENTAL
Intervention: High-fat, high-protein (HFHP) diet
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-fat (HF) diet
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control isocaloric diet
Number of subjects: 10
Study: 17259059

Group type: EXPERIMENTAL
Intervention: Regular use of any of the three substances (alcohol, tobacco, cannabis) at age 14 or 16
Number of subjects: 1322

Group type: COMPARATOR
Intervention: Cigarette‐only and alcohol‐only groups at age 16
Number of subjects: 1322

Group type: EXPERIMENTAL
Intervention: Psychosocial factors (including attitudes to sexual risks and peer sexual norms)
Number of subjects: 1322

Group type: EXPERIMENTAL
Intervention: Greater intercourse frequency and pill use
Number of subjects: 1322
Study: 15115249

Group type: COMPARATOR
Intervention: Standard clamp (insulin‐infusion rate 30 mU kg(‐1) h(‐1), glucose‐target 5.0 mmol/L)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemic clamp (insulin‐infusion rate 150 mU kg(‐1) h(‐1), glucose‐target 5.0 mmol/L)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemic, hyperglycaemic clamp (insulin‐infusion rate 150 mU kg(‐1) h(‐1), glucose‐target 12.0 mmol/L)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Standard clamp
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemic clamp and Hyperinsulinaemic, hyperglycaemic clamp
Number of subjects: 9
Study: 11257150

Group type: EXPERIMENTAL
Intervention: Corticosteroids and pulse cyclophosphamide (0.7 g/m2 at diagnosis) followed by either pulse or oral cyclophosphamide (2 mg/kg/day)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Persistent ANCA
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: ANCA reappearance
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Corticosteroids and cyclophosphamide treatment
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: ANCA negativity
Number of subjects: 55
Study: 9481149

Group type: EXPERIMENTAL
Intervention: Computerized version of the Well-being Questionnaire (WBQ)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Paper and pencil version of the Well-being Questionnaire (WBQ)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Computerized version of the Diabetes Treatment Satisfaction Questionnaire (DTSQ)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Paper and pencil version of the Diabetes Treatment Satisfaction Questionnaire (DTSQ)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Both modes of assessment (WBQ and DTSQ)
Number of subjects: 105
Study: 8149568

Group type: EXPERIMENTAL
Intervention: Diffractive lens
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Front surface aspheric lens
Number of subjects: 25

Group type: COMPARATOR
Intervention: Both lens types
Number of subjects: 25
Study: 2901180

Group type: EXPERIMENTAL
Intervention: Medetomidine (25 micrograms)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Medetomidine (50 micrograms)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Medetomidine (100 micrograms)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 28837949

Group type: EXPERIMENTAL
Intervention: Secure attachment style
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Avoidance and anxiety attachment dimensions
Number of subjects: 103
Study: 27127117

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Trastuzumab treatment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Monitoring activin A concentration
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Activin concentration
Number of subjects: 30
Study: 25002833

Group type: EXPERIMENTAL
Intervention: Prophylactic supplementary nutrition support via gastrostomy immediately following placement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (nutrition support commenced via gastrostomy when clinically indicated during treatment)
Number of subjects: 0
Study: 22897671

Group type: EXPERIMENTAL
Intervention: Stimuplex D Plus (StD+), needle with improved echogenicity
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Stimuplex A (StA), conventional needle
Number of subjects: 15

Group type: COMPARATOR
Intervention: Human control (volunteer)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Embalmed human cadaver
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Pork model
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Turkey model
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Synthetic gel model
Number of subjects: 15
Study: 20485955

Group type: EXPERIMENTAL
Intervention: Hypobaric 0.15% bupivacaine (3 mL, 4.5 mg)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Hypobaric 0.6% lidocaine (3 mL, 18 mg)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Both bupivacaine and lidocaine
Number of subjects: 150
Study: 17573408

Group type: EXPERIMENTAL
Intervention: Prednisolone (5 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 15601276

Group type: EXPERIMENTAL
Intervention: Hamilton Galileo ventilator
Number of subjects: 26

Group type: COMPARATOR
Intervention: Drager CF 800
Number of subjects: 26
Study: 12871461

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (vitamin E at 900 IU day(-1), vitamin C at 2000 mg day(-1)) for 6 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Anti-beta(2) glycoprotein 1 (beta(2)GP(1)) antibodies
Number of subjects: 24

Group type: COMPARATOR
Intervention: APL negative subjects (control group)
Number of subjects: 24
Study: 10479199

Group type: EXPERIMENTAL
Intervention: Broccoli diet (377 microg phylloquinone/d)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Phylloquinone-fortified oil diet (417 microg/d)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Mixed diet only
Number of subjects: 36
Study: 8571024

Group type: EXPERIMENTAL
Intervention: Low-dose hormonal contraceptive (gestodene 75 mcg + ethinylestradiol 30 mcg)
Number of subjects: 1321
Study: 8339236

Group type: EXPERIMENTAL
Intervention: Single-view mammography with extended processing (Kopparberg part of the trial)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two-view mammography with extended processing and grid (British Columbia screening program)
Number of subjects: 0
Study: 3554985

Group type: EXPERIMENTAL
Intervention: Prednisone for seven days plus sulfamethoxazole and trimethoprim for 30 days
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 29274862

Group type: EXPERIMENTAL
Intervention: PMIR-UN (ultrasound guidance)
Number of subjects: 48

Group type: COMPARATOR
Intervention: PMIR-CN (C-arm navigation)
Number of subjects: 48
Study: 27160341

Group type: EXPERIMENTAL
Intervention: High-carotenoid fruit and vegetables (HCFV)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low-carotenoid fruit and vegetables (LCFV)
Number of subjects: 30
Study: 25455039

Group type: EXPERIMENTAL
Intervention: Symbiotic gel (Lactobacillus acidophilus + Bifidobacterium lactis + inulin)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 23462346

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 177

Group type: COMPARATOR
Intervention: Reports of abuse (physical, emotional, sexual)
Number of subjects: 177
Study: 21563884

Group type: EXPERIMENTAL
Intervention: Focal spatial attention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Distributed spatial attention
Number of subjects: 0
Study: 19220966

Group type: EXPERIMENTAL
Intervention: PE+HF group
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: PE group
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77
Study: 16534049

Group type: EXPERIMENTAL
Intervention: Single-dose (1 g) oral azithromycin
Number of subjects: 1452

Group type: EXPERIMENTAL
Intervention: Single-dose azithromycin for household members (20 mg/kg up to 1 g) plus the patient
Number of subjects: 1452

Group type: COMPARATOR
Intervention: Topical tetracycline (twice per day for 6 weeks)
Number of subjects: 1452
Study: 12919237

Group type: EXPERIMENTAL
Intervention: Nurse case management
Number of subjects: 335
Study: 10673249

Group type: EXPERIMENTAL
Intervention: Spironolactone 50 mg/d for 1 month
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 10
Study: 8951438

Group type: EXPERIMENTAL
Intervention: Continuous contralateral white noise at varying levels (10 dB below to 10 dB above the click level)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Click levels at peak sound pressures of 50, 55, 60, 65 and 70 dB
Number of subjects: 0
Study: 1790067

Group type: EXPERIMENTAL
Intervention: Josamycin (750 mg/12 h/orally)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Penicillin V (500 mg/8 h)
Number of subjects: 64
Study: 6805497

Group type: EXPERIMENTAL
Intervention: Biparietal diameter (BPD) measurements known to obstetricians
Number of subjects: 1062

Group type: COMPARATOR
Intervention: Biparietal diameter (BPD) measurements withheld from obstetricians
Number of subjects: 1062
Study: 31718662

Group type: EXPERIMENTAL
Intervention: Erenumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28719717

Group type: EXPERIMENTAL
Intervention: Sildenafil (Viagra) at 50 mg twice a week for 3 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tadalafil (Cialis) at 20 mg twice a week for 3 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vardenafil (Levitra) at 20 mg twice a week for 3 weeks
Number of subjects: 30
Study: 25839920

Group type: EXPERIMENTAL
Intervention: BMI records
Number of subjects: 1310

Group type: EXPERIMENTAL
Intervention: Cerebellar tonsil position measurement
Number of subjects: 1310
Study: 24558764

Group type: EXPERIMENTAL
Intervention: Water-based exercise in thermal mineral water
Number of subjects: 72

Group type: COMPARATOR
Intervention: Land-based exercise therapy
Number of subjects: 72
Study: 21296244

Group type: EXPERIMENTAL
Intervention: Bullard laryngoscope (BL)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: GlideScope videolaryngoscope (GVL)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Viewmax laryngoscope
Number of subjects: 21

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: All devices except Macintosh
Number of subjects: 21
Study: 19244540

Group type: EXPERIMENTAL
Intervention: Sulpiride (D(2) antagonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of sulpiride and L-dopa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: tDCS
Number of subjects: 0
Study: 16723324

Group type: EXPERIMENTAL
Intervention: Regression algorithms to estimate GAI scores
Number of subjects: 1105

Group type: EXPERIMENTAL
Intervention: Regression algorithms to estimate VCI scores
Number of subjects: 1105

Group type: EXPERIMENTAL
Intervention: Regression algorithms to estimate POI scores
Number of subjects: 1105
Study: 15637825

Group type: EXPERIMENTAL
Intervention: Interview with the physician
Number of subjects: 270

Group type: COMPARATOR
Intervention: Self‐administered survey
Number of subjects: 270
Study: 11246096

Group type: EXPERIMENTAL
Intervention: Infant massage class and support group
Number of subjects: 34

Group type: COMPARATOR
Intervention: Support group
Number of subjects: 34
Study: 9224839

Group type: EXPERIMENTAL
Intervention: Experiment 1 - Reaching and grasping with varying distances of the second target.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Experiment 2 - Movements directed towards spatial locations at different distances without a near second target.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Experiment 3 - Reaching and grasping with and without a second near stimulus.
Number of subjects: 0
Study: 8114834

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2a
Number of subjects: 322

Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 322
Study: 3046815

Group type: EXPERIMENTAL
Intervention: 1% atropine, 40 microliters applied in the lower cul-de-sac of one eye
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 8
Study: 31782534

Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 13
Study: 30192928

Group type: EXPERIMENTAL
Intervention: Low-dose scopolamine (0.2 mg IV)
Number of subjects: 0
Study: 27492015

Group type: EXPERIMENTAL
Intervention: Irinotecan 110 mg/m2 on day 1 and 100 mg/m2 on day 8 plus cisplatin 80 mg/m2 on day 8 every 3 weeks (IC arm)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Pemetrexed 500 mg/m2 plus cisplatin 80 mg/m2 on day 1 every 3 weeks (PC arm)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Pemetrexed/cisplatin (PC)
Number of subjects: 124
Study: 25475357

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (1200 mg in divided doses)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 85
Study: 23292661

Group type: EXPERIMENTAL
Intervention: Ultrasonic bone aspirator (UBA)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Traditional steel instrumentation
Number of subjects: 130
Study: 21252212

Group type: EXPERIMENTAL
Intervention: Multiple micronutrients (MMNs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iron/folic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Folic acid
Number of subjects: 0
Study: 18435948

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 1544

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1544
Study: 17098095

Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 20

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 20
Study: 14662281

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg
Number of subjects: 866

Group type: EXPERIMENTAL
Intervention: Continuous combined conjugated equine estrogens plus medroxyprogesterone acetate (0.625 mg/2.5 mg respectively)
Number of subjects: 866

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 866
Study: 10962638

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate
Number of subjects: 0
Study: 8957972

Group type: EXPERIMENTAL
Intervention: 0.25% caudal bupivacaine 0.5 ml kg‐1 and diamorphine 30 micrograms kg‐1
Number of subjects: 45

Group type: COMPARATOR
Intervention: 0.25% caudal bupivacaine 0.5 ml kg‐1 alone
Number of subjects: 45
Study: 1309179

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tracheal tube (TT)
Number of subjects: 20
Study: 3911482

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) initial dose 240 U (anti F Xa)/kg/12 h in study I; 120 U (anti F Xa)/kg/12 h in study II
Number of subjects: 29

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) initial dose 240 U/kg/12 h in both studies
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 29
Study: 31422507

Group type: EXPERIMENTAL
Intervention: Combined upper limb and breathing exercise programme (2 days/week, 60 min/session; independent home exercises 3 days/week, ≥ 20 min/session)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Combined upper limb and breathing exercise programme
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 19
Study: 30343028

Group type: EXPERIMENTAL
Intervention: LABA-ICS
Number of subjects: 12366

Group type: COMPARATOR
Intervention: LAMA
Number of subjects: 12366
Study: 26852337

Group type: EXPERIMENTAL
Intervention: SMS reminders
Number of subjects: 28

Group type: COMPARATOR
Intervention: No SMS reminders
Number of subjects: 28
Study: 23899894

Group type: EXPERIMENTAL
Intervention: Terbutaline (8 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 22342714

Group type: EXPERIMENTAL
Intervention: Taurolidine citrate
Number of subjects: 71

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 71
Study: 20799043

Group type: EXPERIMENTAL
Intervention: Acute strenuous exercise
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Autologous serum exposure 1 hour post-exercise
Number of subjects: 8

Group type: COMPARATOR
Intervention: Autologous serum exposure
Number of subjects: 8